Vidium
Description
We are a new generation of insilico CRO that helps pharma companies accelerating and de-risking the development of innovative treatments exploiting the unprecedent wealth of single cell multi-omic data combined to the power of our unique insilico retro-engineering analysis approach.
Founded in 2018, Vidium introduces a groundbreaking technology that enables the control and mastery of cellular genetic expression. We reconstruct mechanistic and causal digital twins of gene regulatory networks to predict new targets in early R&D phases for the development of "first in class" therapies, or to find biomarkers for patient stratification and drug rescue in clinical phases.
Our goal at Vidium is to revolutionize therapy development by shifting the focus from a single molecular target to the underlying causal gene regulatory network of the cell. We are not another AI company analyzing big data. We design smart experiments that we analyze to make the best predictions for experimental validation.
Our dedication to improving and creating more specific treatments for regenerative medicine, cancer resistance, neurodegenerative, and rare diseases has led us to partner with research, biotech, and pharma institutions to scale target discovery and validation massively. We are committed to leading the charge toward unparalleled innovation in therapy development.
